The stock of Tenaya Therapeutics Inc (NASDAQ: TNYA) has decreased by -13.96% when compared to last closing price of $0.79.Despite this, the company has seen a loss of -19.29% in its stock price over the last five trading days. defenseworld.net reported 2026-01-19 that Corvus Pharmaceuticals (NASDAQ: CRVS – Get Free Report) and Tenaya Therapeutics (NASDAQ: TNYA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations. Institutional and Insider Ownership 46.6% of Corvus
Is It Worth Investing in Tenaya Therapeutics Inc (NASDAQ: TNYA) Right Now?
The 36-month beta value for TNYA is at 3.18. Analysts have varying views on the stock, with 5 analysts rating it as a “buy”, 2 rating it as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for TNYA is 203.21M, and currently, shorts hold a 12.28% of that float. The average trading volume for TNYA on February 12, 2026 was 4.60M shares.
TNYA’s Market Performance
TNYA’s stock has seen a -19.29% decrease for the week, with a -7.80% drop in the past month and a -52.47% fall in the past quarter. The volatility ratio for the week is 12.72%, and the volatility levels for the past 30 days are at 9.96% for Tenaya Therapeutics Inc The simple moving average for the past 20 days is -11.07% for TNYA’s stock, with a -30.55% simple moving average for the past 200 days.
Analysts’ Opinion of TNYA
Leerink Partners, on the other hand, stated in their research note that they expect to see TNYA reach a price target of $7. The rating they have provided for TNYA stocks is “Outperform” according to the report published on November 30th, 2023.
TNYA Trading at -21.05% from the 50-Day Moving Average
After a stumble in the market that brought TNYA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.08% of loss for the given period.
Volatility was left at 9.96%, however, over the last 30 days, the volatility rate increased by 12.72%.
Stock Fundamentals for TNYA
The total capital return value is set at -1.06%. Equity return is now at value -96.44%, with -76.77% for asset returns.
Based on Tenaya Therapeutics Inc (TNYA), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -6.31.
Currently, EBITDA for the company is -$102.66 million with net debt to EBITDA at 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.64.
Conclusion
In conclusion, Tenaya Therapeutics Inc (TNYA) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.